Tazverik (tazemetostat) vs Ogsiveotm (nirogacestat)
Tazverik (tazemetostat) vs Ogsiveotm (nirogacestat)
Tazverik (tazemetostat) is an EZH2 inhibitor approved for the treatment of certain types of epithelioid sarcoma and follicular lymphoma, conditions which are specific types of cancer. On the other hand, Ogsiveotm (nirogacestat) is a gamma-secretase inhibitor that is being investigated for its potential to enhance the activity of other cancer therapies, such as BCMA-targeted therapies in multiple myeloma. When deciding between these medications, it is crucial to consider the specific type of cancer being treated, as their indications and mechanisms of action are different, and a healthcare provider's assessment is necessary to determine the appropriate treatment choice based on the patient's individual diagnosis and overall health status.
Difference between Tazverik and Ogsiveo
| Metric | Tazverik (tazemetostat) | Ogsiveotm (nirogacestat) |
|---|---|---|
| Generic name | Tazemetostat | Nirogacestat |
| Indications | Epithelioid sarcoma, Follicular lymphoma | Desmoid tumors (Investigational) |
| Mechanism of action | Enhancer of zeste homolog 2 (EZH2) inhibitor | Gamma-secretase inhibitor |
| Brand names | Tazverik | Ogsiveotm (proposed) |
| Administrative route | Oral | Oral (Presumed) |
| Side effects | Fatigue, nausea, decreased appetite, vomiting, constipation | Not fully characterized, as it is still investigational |
| Contraindications | None known | None known |
| Drug class | EZH2 inhibitor | Gamma-secretase inhibitor |
| Manufacturer | Epizyme, Inc. | SpringWorks Therapeutics |
Efficacy
Tazverik (Tazemetostat) for Soft Tissue Sarcoma
Tazverik (tazemetostat) is an oral, selective inhibitor of the EZH2 methyltransferase, a key enzyme that can contribute to the proliferation of cancer cells. In the context of soft tissue sarcoma, Tazverik's efficacy has been evaluated in clinical trials, particularly for certain subtypes of sarcoma that are associated with alterations in the EZH2 enzyme or the SWI/SNF complex. These studies have focused on assessing the response rate and duration of response among patients with these specific genetic markers.
However, it is important to note that as of the knowledge cutoff date in early 2023, Tazverik is not specifically approved for the treatment of soft tissue sarcoma. Instead, its approval by the U.S. Food and Drug Administration (FDA) is for the treatment of epithelioid sarcoma, which is a rare subtype of soft tissue sarcoma. The efficacy of Tazverik in other types of soft tissue sarcoma is still under investigation, and further clinical trials are required to establish its safety and effectiveness for these conditions.
Ogsiveotm (Nirogacestat) for Soft Tissue Sarcoma
Ogsiveotm (nirogacestat) is a gamma-secretase inhibitor that is being studied for its potential use in the treatment of desmoid tumors, which are a type of soft tissue sarcoma. Gamma-secretase is an enzyme that can influence the Notch signaling pathway, which plays a role in the growth and progression of certain types of cancer cells. By inhibiting this pathway, nirogacestat aims to reduce tumor growth and improve clinical outcomes for patients with desmoid tumors.
As of the last update, Ogsiveotm (nirogacestat) has not been approved by the FDA for the treatment of soft tissue sarcoma. Clinical trials are ongoing to determine the efficacy and safety of nirogacestat for this indication. Preliminary data from these studies have shown promise, with some patients experiencing stabilization of disease or partial responses. However, comprehensive results and regulatory review are necessary before nirogacestat can be considered a standard treatment option for soft tissue sarcoma or any of its subtypes.
Regulatory Agency Approvals
Tazverik
-
Food and Drug Administration (FDA), USA
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Ogsiveo
-
Food and Drug Administration (FDA), USA
Access Tazverik or Ogsiveo today
If Tazverik or Ogsiveo are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us